- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Sheila Frame: Biosimilars and Cost Reductions for Patients
Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses when patients will see their costs reduced as a result of biosimilars.
Transcript:
Well, it's an immediate opportunity for cost savings. I think from a contracting perspective, as we come into the marketplace, the minute any organization chooses a biosimilar as either a first-line treatment or a second-line treatment or converts from the originator product, then the patient should be seeing those savings immediately.
But, as you know in the US marketplace, transparency isn't necessarily something that everybody's able to get to, right? We can see it, because we contract directly, but the way the US system evolved over time, for lots of good reasons, there's so many people in the middle where the product actually goes through these middlemen, then everyone kind of takes their share. By the time it gets to the patient, it's a $25 copay or it's a $50 copay or it's a deductible.
So I believe that the more transparency that we can bring to the system overall, then the sooner patients are going to see the value and benefit from it.
So, because we have this great evidence now to suggest that biosimilars are just as good from an efficacy and safety perspective, then I think patients are going to be willing to take them on and say, hey, I want to make sure that I get access and that I get access at a fair price and that the system benefits from these products once they're available.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
